CDXS Codexis

Codexis to Present at Two Investment Conferences in March

Codexis to Present at Two Investment Conferences in March

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:

  • Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time).  The conference is being held at the Boston Marriott Copley Place;
  • 32nd Annual Roth Conference on Tuesday, March 17 at 10:30 a.m. Pacific time (1:30 p.m. Eastern time).  The conference is being held at the Ritz Carlton Laguna Niguel in Dana Point, Calif. 

A live webcast and replay of the presentations will be available on the Investors section of the company’s website, .

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see .

Contact: 

LHA Investor Relations

Jody Cain, 310-691-7100

EN
25/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE

Codexis Achieves ISO 9001:2015 Certification

Codexis Achieves ISO 9001:2015 Certification REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The official certification reflects Codexis’s dedication to delivering manufacturing excellence by applying a high standard of quality assurance throughout all of its processes, including research and development, product manufacturing and testing, delivery, support, and customer service. “Quality ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch